Better moods, higher concentration levels, more creativity - and all without the usual risks associated with hard drugs: Proponents of microdosing LSD - taking tiny fractions of the amount needed for ...

Microdosing lysergic acid diethylamide (LSD) involves taking a very small dose of the substance. Advocates of LSD microdosing claim the practice has numerous health benefits, such as improving ...

A landmark clinical trial testing the effect of microdosing LSD on symptoms of attention-deficit hyperactive disorder (ADHD) recently delivered its first data readout and the results have been ...

MindBio Therapeutics Corp. said that “MB22001, a proprietary and self-titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take home microdosing” has been approved for take-home use ...

LSD has shown promise for treating conditions like depression, but it might not do much for ADHD. © cybermagician via Shutterstock LSD can do a lot of things, but ...

Just weeks after a double-blind, placebo-controlled trial found psilocybin microdosing to be no different to placebo, another study has been published that found LSD microdoses have no effect on mood ...

Proponents of LSD “microdosing” -- taking small amounts of the drug at regular intervals -- claim it can improve mood and cognitive function. But new research by the University of Chicago has not ...

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder was feasible and well-tolerated, with Montgomery-Åsberg Depression Rating ...

Microdosing has become trendy in the era of drug legalization, with TV shows like "Nine Perfect Strangers" promoting the potential positives of regularly taking tiny amounts of psychedelics. But a new ...

In a recent study published in the journal Translational Psychiatry, researchers from New Zealand conducted a phase I trial to assess the effect of micro-dosing of lysergic acid diethylamide (LSD) on ...

Australian R&D company MindBio Therapeutics conducted a first-ever Phase 2a take-home microdosing trial to treat depression.. 53% of patients went into complete depression remission after 8 weeks of ...

Holding company Blackhawk Growth Corp.BLRZF's subsidiary company MindBio Therapeutics Pty Ltd shared the positive data gathered from its Phase 1 clinical trials microdosing LSD formulation in 80 ...